Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2017

Open Access 01-12-2017 | Research

Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement

Authors: Kimberley Legge, Peter B. Greer, Daryl J. O’Connor, Lee Wilton, Matthew Richardson, Perry Hunter, Alex Wilfert, Jarad Martin, Anatoly Rosenfeld, Dean Cutajar

Published in: Radiation Oncology | Issue 1/2017

Login to get access

Abstract

Background

MOSFET dosimetry is a method that has been used to measure in-vivo doses during brachytherapy treatments and during linac based radiotherapy treatment. Rectal displacement devices (RDDs) allow for safe dose escalation for prostate cancer treatment. This study used dual MOSkin detectors to assess real-time in vivo rectal wall dose in patients with an RDD in place during a high dose prostate stereotactic body radiation therapy (SBRT) boost trial.

Methods

The PROMETHEUS study commenced in 2014 and provides a prostate SBRT boost dose with a RDD in place. Twelve patients received two boost fractions of 9.5–10 Gy each delivered to the prostate with a dual arc volumetric modulated arc therapy (VMAT) technique. Two MOSkins in a face-to-face arrangement (dual MOSkin) were used to decrease angular dependence. A dual MOSkin was attached to the anterior surface of the Rectafix and read out at 1 Hz during each treatment. The planned dose at each measurement point was exported from the planning system and compared with the measured dose. The root mean square error normalised to the total planned dose was calculated for each measurement point and treatment arc for the entire course of treatment.

Results

The average difference between the measured and planned doses over the whole course of treatment for all arcs measured was 9.7% with a standard deviation of 3.6%. The cumulative MOSkin reading was lower than the total planned dose for 64% of the arcs measured. The average difference between the final measured and final planned doses for all arcs measured was 3.4% of the final planned dose, with a standard deviation of 10.3%.

Conclusions

MOSkin detectors were an effective tool for measuring dose delivered to the anterior rectal wall in real time during prostate SBRT boost treatments for the purpose of both ensuring the rectal doses remain within acceptable limits during the treatment and for the verification of final rectal doses.
Literature
1.
Vogelius R, Bentzen SM. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: bad news, good news, or no news? Int J Radiat Oncol Biol Phys. 2013;85:89–94.CrossRefPubMed
2.
Williams G, Taylor JM, Liu N. Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:24–33.CrossRefPubMed
3.
Hoskin PJ, Motohashi K, Bownes P, Bryant L, Ostler P. High dose rate brachytherapy in combination with external beam radiotherapy in the radical treatment of prostate cancer: initial results of a randomised phase three trial. Radiother Oncol. 2007;84:114–20.CrossRefPubMed
4.
Khor R, Duchesne G, Tai K-H, Foroudi F, Chander S, Van Dyk S, Garth M, Williams S. Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys. 2013;85:679–85.CrossRefPubMed
5.
Zwahlen DR, Andrianopoulos N, Matheson B, Duchesne GM, Millar JL. High-dose-rate brachytherapy in combination with conformal external beam radiotherapy in the treatment of prostate cancer. Brachytherapy. 2010;9:27–35.CrossRefPubMed
6.
Oermann EK, Slack RS, Hanscom HN, Lei S, Suy S, Park HU, Kim JS, Sherer BA, Collins BT, Satinsky AN, Harter KW, Batipps GP, Constantinople NL, Dejter SW, Maxted WC, Regan JB, Pahira JJ, McGeagh KG, Jha RC, Dawson NA, Dritschilo A, Lynch JH, Collins SP. A pilot study of intensity modulated radiation therapy with hypofractionated stereotactic body radiation therapy (SBRT) boost in the treatment of intermediate- to high-risk prostate cancer. Technol Cancer Res Treat. 2010;9:453–62.CrossRefPubMed
7.
Jabbari S, Weinberg VK, Kaprealian T, Hsu IC, Ma L, Chuang C, Descovich M, Shiao S, Shinohara K, Roach Iii M, Gottschalk AR. Stereotactic body radiotherapy as monotherapy or post-external beam radiotherapy boost for prostate cancer: technique, early toxicity, and PSA response. Int J Radiat Oncol Biol Phys. 2012;82:228–34.CrossRefPubMed
8.
Katz AJ, Santoro M, Ashley R, Diblasio F, Witten M. Stereotactic body radiotherapy as boost for organ-confined prostate cancer. Technol Cancer Res Treat. 2010;9:575–82.CrossRefPubMed
9.
Xie Y, Djajaputra D, King CR, Hossain S, Ma L, Xing L. Intrafractional motion of the prostate during hypofractionated radiotherapy. Int J Radiat Oncol Biol Phys. 2008;72:236–46.CrossRefPubMedPubMedCentral
10.
Hanks GE, Schultheiss TE, Hanlon AL, Hunt M, Lee WR, Epstein BE, Coia LR. Optimization of conformal radiation treatment of prostate cancer: report of a dose escalation study. Int J Radiat Oncol Biol Phys. 1997;37:543–50.CrossRefPubMed
11.
Valdagni R, Rancati T. Reducing rectal injury during external beam radiotherapy for prostate cancer. Nat Rev Urol. 2013;10:345–57.CrossRefPubMed
12.
Isacsson U, Nilsson K, Asplund S, Morhed E, Montelius A, Turesson I. A method to separate the rectum from the prostate during proton beam radiotherapy of prostate cancer patients. Acta Oncol. 2010;49:500–5.CrossRefPubMed
13.
Archambault L, Briere TM, Pönisch F, Beaulieu L, Kuban DA, Lee A, Beddar S. Toward a Real-Time In Vivo Dosimetry System Using Plastic Scintillation Detectors. Int J Radiat Oncol Biol Phys. 2010;78:280–7.CrossRefPubMedPubMedCentral
14.
Gambarini G, Carrara M, Tenconi C, Mantaut N, Borroni M, Cutajar D, Petasecca M, Fuduli I, Lerch M, Pignoli E, Rosenfeld A. Online in vivo dosimetry in high dose rate prostate brchytherapy with MOSkin detectors: in phantom feasibility study. Appl Radiat Isot. 2014;83:222–6.CrossRefPubMed
15.
Alnaghy SJ, Deshpande S, Cutajar DL, Berk K, Metcalfe P, Rosenfeld AB. In vivo endorectal dosimetry of prostate tomotherapy using dual MOSkin detectors. J Appl Clin Med Phys. 2015;16:5113.PubMed
16.
Tenconi C, Carrara M, Borroni M, Cerrotta A, Cutajar D, Petasecca M, Lerch M, Bucci J, Gambarini G, Pignoli E, Rosenfeld A. TRUS-probe integrated MOSkin detectors for rectal wall in vivo dosimetry in HDR brachytherapy: in phantom feasibility study. Radiat Meas. 2014;71:379–83.CrossRef
17.
Wootton L, Kudchadker R, Lee A, Beddar S. Real-time in vivo rectal wall dosimetry using plastic scintillation detectors for patients with prostate cancer. Phys Med Biol. 2014;59:647–60.CrossRefPubMedPubMedCentral
18.
Carrara M, Tenconi C, Rossi G, Borroni M, Cerrotta A, Grisotto S, Cusumano D, Pappalardi B, Cutajar D, Petasecca M, Lerch M, Gambarini G, Fallai C, Rosenfeld A, Pignoli E. In vivo rectal wall measurements during HDR prostate brachytherapy with MOSkin dosimeters integrated on a trans-rectal US probe: comparison with planned and reconstructed doses. Radiother Oncol. 2016;118:148–53.CrossRefPubMed
19.
Kwan IS, Rosenfeld AB, Qi ZY, Wilkinson D, Lerch MLF, Cutajar DL, Safavi-Naeni M, Butson M, Bucci JA, Chin Y, Perevertaylo VL. Skin dosimetry with new MOSFET detectors. Radiat Meas. 2008;43:929–32.CrossRef
20.
Hardcastle N, Cutajar D, Metcalfe P, Lerch MLF, Perevertaylo VL, Tome WA, Rosenfeld A. In vivo real-time rectal wall dosimetry for prostate radiotherapy. Phys Med Biol. 2010;55:3859–71.CrossRefPubMedPubMedCentral
21.
Cheung T, Martin JB, Peter KNY. Effects of temperature variation on MOSFET dosimetry. Phys Med Biol. 2004;49:N191.CrossRefPubMed
22.
Rosenfeld AB, Siegbahn EA, Brauer-Krish E, Holmes-Siedle A, Lerch MLF, Bravin A, Cornelius IM, Takacs GJ, Painuly N, Nettelback H, Kron T. Edge-on face-to-face MOSFET for synchrotron microbeam dosimetry: MC modeling. IEEE Trans Nucl Sci. 2005;52:2562–9.CrossRef
Metadata
Title
Real-time in vivo rectal wall dosimetry using MOSkin detectors during linac based stereotactic radiotherapy with rectal displacement
Authors
Kimberley Legge
Peter B. Greer
Daryl J. O’Connor
Lee Wilton
Matthew Richardson
Perry Hunter
Alex Wilfert
Jarad Martin
Anatoly Rosenfeld
Dean Cutajar
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2017
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-017-0781-4

Other articles of this Issue 1/2017

Radiation Oncology 1/2017 Go to the issue

Research

Long-term follow-up after stereotactic radiosurgery of intracanalicular acoustic neurinoma

Research

Understanding the potentiality of accelerator based-boron neutron capture therapy for osteosarcoma: dosimetry assessment based on the reported clinical experience

Research

Subventricular zones: new key targets for glioblastoma treatment

Research

Significant benefits in survival by the use of surgery combined with radiotherapy for retroperitoneal soft tissue sarcoma

Review

Stereotactic radiosurgery versus whole-brain radiotherapy after intracranial metastasis resection: a systematic review and meta-analysis

Research

Cone-beam CT reconstruction for non-periodic organ motion using time-ordered chain graph model